off-label use of glp-1 agonists for obesity in 2016 Ozempic Goes Way Upgrading from Overweight: The Effects

Description

Drugs that will produce 15 percent body weight loss we did not have that before in the medical therapy of obesity. With additional, potentially more effective GLP-1 receptor agonists coming online in the future, were at the beginning of a promising new chapter of obesity therapeutics

Toxicities of opioid analgesics: respiratory depression, histamine release, hemodynamic changes, hypersensitivity, serotonin toxicity

Saxenda is sometimes prescribed off-label for metabolic dysfunction-associated steatohepatitis (MASH)

The study emphasizes the necessity of more investigation to comprehend the processes behind these impacts on fracture risk and bone metabolism ( It has been demonstrated that GLP-1 agonists significantly increase the mass of the femur and vertebrae ( In individuals with T2DM, the risk of fractures was assessed using a network meta-analysis and systematic review to determine the relationship between dipeptidyl peptidase-4 inhibitors (DPP-4i), GLP-1 RAs, and sodium-glucose cotransporter-2 inhibitors (SGLT-2i)